source
- Hemab Therapeutics IPO raises $301.5M, stock triples and funds runway to 2029Hemab Therapeutics completed an upsized $301.5 million IPO in May, boosting total proceeds to $346.7 million. The offering helped the company’s share price climb from $18 at debut to $53.48 by mid‑…
- Deerfield-backed Boulevard Bio raises $65 million and unveils three autoimmune drug candidatesBoulevard Bio, a New York‑based biotech focused on B‑cell biology, announced it has emerged from stealth with $65 million in financing from Deerfield Management. The funding supports the developmen…